On Tuesday, Xilio Therapeutics Inc (NASDAQ: XLO) was 11.40% up from the session before settling in for the closing price of $1.14. A 52-week range for XLO has been $0.50 – $1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 58.99%. With a float of $19.67 million, this company’s outstanding shares have now reached $43.96 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 82.23%, operating margin of -852.23%, and the pretax margin is -834.92%.
Xilio Therapeutics Inc (XLO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Xilio Therapeutics Inc stocks. The insider ownership of Xilio Therapeutics Inc is 55.26%, while institutional ownership is 16.09%. The most recent insider transaction that took place on Jan 02 ’25, was worth 6,841. In this transaction Chief Financial Officer of this company sold 6,954 shares at a rate of $0.98, taking the stock ownership to the 12,421 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, FINANCE AND ACCOUNTING sold 1,803 for $0.98, making the entire transaction worth $1,774. This insider now owns 3,197 shares in total.
Xilio Therapeutics Inc (XLO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.99% per share during the next fiscal year.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
You can see what Xilio Therapeutics Inc (XLO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.72, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Xilio Therapeutics Inc (XLO)
Looking closely at Xilio Therapeutics Inc (NASDAQ: XLO), its last 5-days average volume was 0.34 million, which is a drop from its year-to-date volume of 0.39 million. As of the previous 9 days, the stock’s Stochastic %D was 79.76%. Additionally, its Average True Range was 0.12.
During the past 100 days, Xilio Therapeutics Inc’s (XLO) raw stochastic average was set at 67.66%, which indicates a significant decrease from 97.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.28% in the past 14 days, which was lower than the 123.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0391, while its 200-day Moving Average is $0.9917. However, in the short run, Xilio Therapeutics Inc’s stock first resistance to watch stands at $1.3233. Second resistance stands at $1.3765. The third major resistance level sits at $1.4732. If the price goes on to break the first support level at $1.1734, it is likely to go to the next support level at $1.0767. Now, if the price goes above the second support level, the third support stands at $1.0235.
Xilio Therapeutics Inc (NASDAQ: XLO) Key Stats
There are 43,958K outstanding shares of the company, which has a market capitalization of 58.11 million. As of now, sales total 0 K while income totals -76,400 K. Its latest quarter income was 2,260 K while its last quarter net income were -14,020 K.
